Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to
demonstrate statistically significant extension of survival in newly
diagnosed glioblastoma patients

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering
a novel therapy for solid tumors, announced today it will offer on
demand Optune certification training for the radiation oncology
community at the American Society for Therapeutic Radiology and Oncology
(ASTRO) 57th Annual Meeting in San Antonio, Texas from
October 18 through October 20, 2015. Optune was approved by the FDA on
October 5, 2015 for the treatment of newly diagnosed glioblastoma (GBM)
in combination with temozolomide. Optune’s Instructions for Use (IFU)
require that prescribing medical personnel complete a training course
provided by Novocure. Novocure is committed to making this training
widely available for radiation oncologists, given their critical role in
the treatment of newly diagnosed GBM patients.

Optune is the first FDA-approved therapy in more than a decade to
demonstrate statistically significant extension of overall survival in
newly diagnosed GBM. The two-year survival rate among patients treated
with Optune in combination with temozolomide was 50% higher than in
patients treated with temozolomide alone. No significant additive
systemic toxicity was observed in the trial, and patients maintained
stable quality-of-life, cognitive function and activities of daily
living while using Optune.

“We are pleased to offer such a convenient training opportunity for
radiation oncologists at ASTRO,” said Peter Melnyk, Novocure’s Chief
Commercial Officer. “Novocure is committed to helping patients with
glioblastoma and we know that the radiation oncology community will be
an invaluable partner as we work together to bring this life-extending
therapy to patients with newly diagnosed GBM.”

Certification training will be offered on location Sunday, October 18
through Tuesday, October 20, 2015. A sign-up sheet will be available at
the Novocure exhibit, booth 1759.

Additional Novocure Activities at ASTRO

In addition to the certification training, Novocure will have four
poster presentations describing the latest aspects of Tumor Treating
Fields (TTFields) therapy at the meeting. Details on the poster
presentations are as follows:

Modeling inter-subject differences in Tumor Treating Fields (TTFields)
treatment of GBM patients
Presenter: Wenger C et al

NovoTTF™-100A system (Tumor Treating Fields) transducer array layout
planning for glioblastoma: results of a NovoTAL™ system user study
Chaudhry A et al

Optimizing the delivery of TTFields to the lungs by personalizing
transducer array layouts on the torso
Presenter: Bomson Z et al

Tumor Treating Fields (TTFields) sensitize glioma tumor cells to
radiation therapy by delaying DNA damage repair through homologous
Presenter: Giladi M et al

Novocure will have an exhibit, booth 1759, where the radiation oncology
community can meet with commercial and medical colleagues and learn more
about Optune. Novocure will also host a company information session and
sponsor an industry expert theatre to provide education on the newly
diagnosed GBM indication for Optune, as detailed below:

Novocure Informational Session
Date: Sunday, October
18, 2015
Time: 6:30 p.m. to 8:30 p.m.
Grand Hyatt, Bowie B, Second floor

Industry Expert Theatre: Tumor Treating Fields: Understanding
Treatment with Optune

Faculty: Dr. Jeremy Rudnick,
Cedars-Sinai Medical Center
Date: Tuesday, October 20, 2015
11:45 a.m. to 12:45 p.m.
Location: Theatre 1, Exhibition
Hall, Henry Gonzales Convention Center

“We are thrilled to have a significant presence at ASTRO’s annual
meeting and look forward to introducing Optune for newly diagnosed GBM
to this important clinical community,” said Pritesh Shah, Novocure’s US
General Manager. “Both Novocure and radiation oncologists treat
glioblastoma with a physical modality and we believe there is a natural
fit for us to work together to bring Tumor Treating Fields therapy to

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable,
non-invasive medical device designed for continuous use by patients. In
and in vivo studies have shown that TTFields therapy
slows and reverses tumor growth by inhibiting mitosis, the process by
which cells divide and replicate. TTFields therapy creates low
intensity, alternating electric fields within a tumor that exert
physical forces on electrically charged cellular components, preventing
the normal mitotic process and causing cancer cell death.

Approved Indications

Optune is intended as a treatment for adult patients (22 years of age or
older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult
patients with newly diagnosed, supratentorial glioblastoma following
maximal debulking surgery and completion of radiation therapy together
with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following
histologically-or radiologically-confirmed recurrence in the
supra-tentorial region of the brain after receiving chemotherapy. The
device is intended to be used as a monotherapy, and is intended as an
alternative to standard medical therapy for GBM after surgical and
radiation options have been exhausted.

Patients should only use Optune under the supervision of a physician
properly trained in use of the device. Full prescribing information is
available at
or by calling toll free 1-855-281-9301.

About Novocure

Novocure is a Jersey Isle oncology company pioneering a novel therapy
for solid tumors called TTFields. Novocure’s US operations are based in
Portsmouth, NH and New York, NY. Additionally, the company has offices
in Germany, Switzerland, and Japan and a research center in Haifa,
Israel. For additional information about the company, please visit
or follow us at

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its prospectus
dated October 1, 2015 filed with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.


Media and Investor Contact:
Ashley Cordova,